DNTH

+ Watchlist + Portfolio

Dianthus Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $88.32
52-Week Range: $32.22 – $117.88
Market Cap: $4.82B
P/E (TTM): —
EPS (TTM): -4.24
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 4.12
PEG Ratio: —
Return on Equity: -26.06%
Return on Assets: -17.69%
Gross Margin: 100.00%
Operating Margin: -8079.11%
Profit Margin: 0.00%
Current Ratio: 26.10
Debt/Equity: 0.00
Total Debt: $1.29M
Free Cash Flow: $-92.21M
Revenue Growth: 294.30%
Earnings Growth: —
Enterprise Value: $4.05B

DNTH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$6.42M	$2.83M	$6.24M	$2.04M
Research & Development	$29.38M	$32.84M	$83.11M	$145.64M
Selling, General & Admin	$6.74M	$18.16M	$24.99M	$34.33M
Operating Expenses	$36.12M	$51.00M	$108.10M	$179.97M
Operating Income	-$29.70M	-$48.17M	-$101.86M	-$177.93M
EBITDA	-$29.56M	-$47.82M	-$101.45M	-$177.50M
Pretax Income	-$28.48M	-$43.55M	-$84.97M	-$162.34M
Net Income	-$28.48M	-$43.55M	-$84.97M	-$162.34M
Diluted EPS	-1.92	-8.45	-2.55	-4.20
Diluted Shares	14.82M	5.15M	33.31M	38.62M

DNTH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$15.37M	$132.32M	$22.79M	$51.09M
Receivables	$5.64M	$478.00K	$807.00K	$52.00K
Current Assets	$82.03M	$177.45M	$280.90M	$409.44M
Total Assets	$83.11M	$179.41M	$374.01M	$530.92M
Current Liabilities	$8.22M	$9.63M	$18.45M	$30.73M
Total Debt	$788.00K	$585.00K	$1.49M	$1.39M
Total Liabilities	$9.45M	$10.54M	$21.53M	$37.52M
Retained Earnings	-$45.87M	-$89.42M	-$174.39M	-$336.73M
Shareholders' Equity	$73.66M	$168.87M	$352.48M	$493.40M
Working Capital	$73.81M	$167.82M	$262.45M	$378.71M

DNTH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$29.07M	-$36.86M	-$78.18M	-$129.06M
Capital Expenditure	-$139.00K	-$110.00K	-$105.00K	-$213.00K
Free Cash Flow	-$29.21M	-$36.97M	-$78.28M	-$129.27M
Depreciation & Amortisation	$147.00K	$355.00K	$412.00K	$428.00K
Stock-Based Compensation	$1.52M	$2.90M	$12.89M	$22.79M
Investing Cash Flow	-$59.82M	$20.25M	-$286.81M	-$122.83M
Financing Cash Flow	$96.68M	$133.57M	$255.62M	$280.13M
Net Change in Cash	$7.79M	$116.97M	-$109.37M	$28.23M

DNTH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.16M	$193.00K	$396.00K	$284.00K	$463.00K	$761.00K
Research & Development	$27.00M	$26.25M	$32.49M	$59.90M	$34.53M	$48.69M
Selling, General & Admin	$7.34M	$8.87M	$8.20M	$9.93M	$12.47M	$13.56M
Operating Expenses	$34.34M	$35.12M	$40.68M	$69.83M	$47.00M	$62.24M
Operating Income	-$33.18M	-$34.93M	-$40.29M	-$69.54M	-$46.53M	-$61.48M
EBITDA	-$33.04M	-$34.83M	-$40.19M	-$69.44M	-$46.46M	-$61.38M
Pretax Income	-$29.51M	-$31.63M	-$36.77M	-$64.43M	-$40.83M	-$50.22M
Net Income	-$29.51M	-$31.63M	-$36.77M	-$64.43M	-$40.83M	-$50.22M
Diluted EPS	-0.82	-0.88	-0.97	-1.43	-0.85	-0.90
Diluted Shares	35.79M	35.82M	37.79M	44.97M	48.03M	56.03M

DNTH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$10.12M	$13.24M	$55.98M	$51.09M	$627.67M	$110.55M
Receivables	$1.00M	$39.00K	$5.00M	$52.00K	$1.23M	$106.00K
Current Assets	$271.00M	$263.61M	$413.82M	$409.44M	$1.12B	$897.54M
Total Assets	$348.58M	$326.08M	$577.45M	$530.92M	$1.25B	$1.21B
Current Liabilities	$16.95M	$20.09M	$23.86M	$30.73M	$38.28M	$34.39M
Total Debt	$1.40M	$1.33M	$1.28M	$1.39M	$1.36M	$1.29M
Total Liabilities	$19.97M	$23.00M	$30.99M	$37.52M	$45.57M	$41.25M
Retained Earnings	-$203.90M	-$235.53M	-$272.30M	-$336.73M	-$377.56M	-$427.78M
Shareholders' Equity	$328.61M	$303.08M	$546.45M	$493.40M	$1.20B	$1.17B
Working Capital	$254.05M	$243.51M	$389.97M	$378.71M	$1.08B	$863.15M

DNTH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$27.63M	-$23.89M	-$30.55M	-$46.98M	-$28.86M	-$48.98M
Capital Expenditure	-$24.00K	-$46.00K	-$5.00K	-$138.00K	-$10.00K	-$181.00K
Free Cash Flow	-$27.65M	-$23.94M	-$30.56M	-$47.12M	-$28.87M	-$49.16M
Depreciation & Amortisation	$133.00K	$99.00K	$99.00K	$97.00K	$76.00K	$107.00K
Stock-Based Compensation	$5.32M	$5.71M	$5.79M	$5.98M	$10.60M	$11.90M
Investing Cash Flow	$14.79M	$26.45M	-$201.28M	$37.20M	-$133.97M	-$478.52M
Financing Cash Flow	$161.00K	$568.00K	$274.51M	$4.88M	$739.41M	$10.38M
Net Change in Cash	-$12.68M	$3.12M	$42.68M	-$4.90M	$576.58M	-$517.12M

Market Snapshot

About

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for complement-mediated autoimmune and inflammatory diseases. The company's lead program targets rare diseases where the complement system, a part of the immune system, causes tissue damage. Dianthus is advancing therapies designed to selectively inhibit specific components of the complement cascade. The company's pipeline addresses significant unmet medical needs in conditions with limited treatment options.